nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—ACHE—prostate cancer	0.31	0.783	CbGaD
Galantamine—CYP3A4—prostate cancer	0.0858	0.217	CbGaD
Galantamine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0331	0.154	CbGbCtD
Galantamine—CYP2D6—Bicalutamide—prostate cancer	0.0273	0.128	CbGbCtD
Galantamine—CYP2D6—Abiraterone—prostate cancer	0.0227	0.106	CbGbCtD
Galantamine—CYP3A4—Bicalutamide—prostate cancer	0.0174	0.0811	CbGbCtD
Galantamine—CYP3A4—Estramustine—prostate cancer	0.0162	0.0754	CbGbCtD
Galantamine—CYP3A4—Abiraterone—prostate cancer	0.0144	0.0672	CbGbCtD
Galantamine—CYP3A4—Flutamide—prostate cancer	0.0144	0.0672	CbGbCtD
Galantamine—CYP3A4—Cabazitaxel—prostate cancer	0.0107	0.0497	CbGbCtD
Galantamine—CYP3A4—Estrone—prostate cancer	0.0104	0.0486	CbGbCtD
Galantamine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00928	0.0433	CbGbCtD
Galantamine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00681	0.0318	CbGbCtD
Galantamine—CYP3A4—Mitoxantrone—prostate cancer	0.00619	0.0289	CbGbCtD
Galantamine—CYP3A4—Estradiol—prostate cancer	0.00598	0.0279	CbGbCtD
Galantamine—CHRNA5—prostate gland—prostate cancer	0.00525	0.094	CbGeAlD
Galantamine—CYP3A4—Prednisone—prostate cancer	0.00514	0.024	CbGbCtD
Galantamine—CYP2D6—Doxorubicin—prostate cancer	0.00419	0.0196	CbGbCtD
Galantamine—CYP3A4—Etoposide—prostate cancer	0.00391	0.0182	CbGbCtD
Galantamine—CHRNG—prostate gland—prostate cancer	0.00375	0.0671	CbGeAlD
Galantamine—CYP3A4—Docetaxel—prostate cancer	0.00357	0.0167	CbGbCtD
Galantamine—CHRNE—testis—prostate cancer	0.00331	0.0592	CbGeAlD
Galantamine—CHRNG—seminal vesicle—prostate cancer	0.00317	0.0568	CbGeAlD
Galantamine—CHRNA5—Fulvestrant—Estradiol—prostate cancer	0.00314	1	CbGdCrCtD
Galantamine—CYP3A4—Doxorubicin—prostate cancer	0.00266	0.0124	CbGbCtD
Galantamine—CHRNA1—prostate gland—prostate cancer	0.00249	0.0444	CbGeAlD
Galantamine—CHRNA5—testis—prostate cancer	0.00231	0.0414	CbGeAlD
Galantamine—CHRNB2—prostate gland—prostate cancer	0.00229	0.0409	CbGeAlD
Galantamine—CHRNA3—prostate gland—prostate cancer	0.00222	0.0397	CbGeAlD
Galantamine—CHRNA2—prostate gland—prostate cancer	0.00206	0.0369	CbGeAlD
Galantamine—CHRNG—bone marrow—prostate cancer	0.00193	0.0346	CbGeAlD
Galantamine—CHRNB1—prostate gland—prostate cancer	0.00192	0.0343	CbGeAlD
Galantamine—CHRNA5—lymph node—prostate cancer	0.00168	0.03	CbGeAlD
Galantamine—ACHE—prostate gland—prostate cancer	0.00166	0.0298	CbGeAlD
Galantamine—CHRNB4—testis—prostate cancer	0.00159	0.0285	CbGeAlD
Galantamine—CYP3A4—urine—prostate cancer	0.00153	0.0274	CbGeAlD
Galantamine—CHRNB2—urethra—prostate cancer	0.00153	0.0274	CbGeAlD
Galantamine—CYP2D6—urine—prostate cancer	0.00151	0.027	CbGeAlD
Galantamine—Morphine—UGT2B15—prostate cancer	0.00149	0.375	CrCbGaD
Galantamine—CHRNA10—testis—prostate cancer	0.0014	0.0251	CbGeAlD
Galantamine—CHRNB2—bone marrow—prostate cancer	0.00118	0.0211	CbGeAlD
Galantamine—CHRNA10—lymph node—prostate cancer	0.00102	0.0182	CbGeAlD
Galantamine—CHRNB2—testis—prostate cancer	0.00101	0.018	CbGeAlD
Galantamine—CHRNA7—renal system—prostate cancer	0.000988	0.0177	CbGeAlD
Galantamine—CHRNA3—testis—prostate cancer	0.000977	0.0175	CbGeAlD
Galantamine—CHRNB1—testis—prostate cancer	0.000845	0.0151	CbGeAlD
Galantamine—BCHE—prostate gland—prostate cancer	0.000818	0.0146	CbGeAlD
Galantamine—CHRFAM7A—testis—prostate cancer	0.00079	0.0141	CbGeAlD
Galantamine—ACHE—testis—prostate cancer	0.000733	0.0131	CbGeAlD
Galantamine—CHRNB2—lymph node—prostate cancer	0.00073	0.0131	CbGeAlD
Galantamine—CHRNA3—lymph node—prostate cancer	0.000708	0.0127	CbGeAlD
Galantamine—BCHE—seminal vesicle—prostate cancer	0.000692	0.0124	CbGeAlD
Galantamine—CHRNA7—testis—prostate cancer	0.000638	0.0114	CbGeAlD
Galantamine—CHRNB1—lymph node—prostate cancer	0.000613	0.011	CbGeAlD
Galantamine—ACHE—lymph node—prostate cancer	0.000531	0.0095	CbGeAlD
Galantamine—Codeine—SLC22A1—prostate cancer	0.000495	0.125	CrCbGaD
Galantamine—BCHE—bone marrow—prostate cancer	0.000421	0.00754	CbGeAlD
Galantamine—Oxycodone—CYP3A5—prostate cancer	0.000419	0.105	CrCbGaD
Galantamine—Codeine—CYP3A5—prostate cancer	0.000399	0.101	CrCbGaD
Galantamine—CYP3A4—renal system—prostate cancer	0.000375	0.00671	CbGeAlD
Galantamine—CYP2D6—renal system—prostate cancer	0.000369	0.0066	CbGeAlD
Galantamine—BCHE—testis—prostate cancer	0.00036	0.00644	CbGeAlD
Galantamine—BCHE—lymph node—prostate cancer	0.000261	0.00467	CbGeAlD
Galantamine—Dihydrocodeine—CYP3A4—prostate cancer	0.000259	0.0653	CrCbGaD
Galantamine—CYP2D6—testis—prostate cancer	0.000239	0.00427	CbGeAlD
Galantamine—Ethylmorphine—CYP3A4—prostate cancer	0.000217	0.0547	CrCbGaD
Galantamine—Hydrocodone—CYP3A4—prostate cancer	0.000199	0.05	CrCbGaD
Galantamine—Oxycodone—CYP3A4—prostate cancer	0.000181	0.0457	CrCbGaD
Galantamine—Codeine—CYP3A4—prostate cancer	0.000173	0.0436	CrCbGaD
Galantamine—Morphine—CYP3A4—prostate cancer	0.00014	0.0353	CrCbGaD
Galantamine—Hepatitis—Epirubicin—prostate cancer	5.35e-05	0.00024	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—prostate cancer	5.35e-05	0.00024	CcSEcCtD
Galantamine—Thrombocytopenia—Capecitabine—prostate cancer	5.35e-05	0.00024	CcSEcCtD
Galantamine—Syncope—Prednisone—prostate cancer	5.34e-05	0.00024	CcSEcCtD
Galantamine—Tachycardia—Capecitabine—prostate cancer	5.33e-05	0.000239	CcSEcCtD
Galantamine—Skin disorder—Capecitabine—prostate cancer	5.3e-05	0.000238	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—prostate cancer	5.29e-05	0.000237	CcSEcCtD
Galantamine—Hyperhidrosis—Capecitabine—prostate cancer	5.28e-05	0.000237	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—prostate cancer	5.27e-05	0.000237	CcSEcCtD
Galantamine—Hypotension—Docetaxel—prostate cancer	5.27e-05	0.000237	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—prostate cancer	5.26e-05	0.000236	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—prostate cancer	5.26e-05	0.000236	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—prostate cancer	5.25e-05	0.000236	CcSEcCtD
Galantamine—Loss of consciousness—Prednisone—prostate cancer	5.24e-05	0.000235	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—prostate cancer	5.22e-05	0.000234	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—prostate cancer	5.21e-05	0.000234	CcSEcCtD
Galantamine—Anorexia—Capecitabine—prostate cancer	5.2e-05	0.000234	CcSEcCtD
Galantamine—Nausea—Estradiol—prostate cancer	5.2e-05	0.000234	CcSEcCtD
Galantamine—Vomiting—Mitoxantrone—prostate cancer	5.19e-05	0.000233	CcSEcCtD
Galantamine—Convulsion—Prednisone—prostate cancer	5.16e-05	0.000232	CcSEcCtD
Galantamine—Visual impairment—Epirubicin—prostate cancer	5.16e-05	0.000232	CcSEcCtD
Galantamine—Hypertension—Prednisone—prostate cancer	5.14e-05	0.000231	CcSEcCtD
Galantamine—Rash—Mitoxantrone—prostate cancer	5.14e-05	0.000231	CcSEcCtD
Galantamine—Dermatitis—Mitoxantrone—prostate cancer	5.14e-05	0.000231	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Docetaxel—prostate cancer	5.14e-05	0.000231	CcSEcCtD
Galantamine—Headache—Mitoxantrone—prostate cancer	5.11e-05	0.00023	CcSEcCtD
Galantamine—Hypotension—Capecitabine—prostate cancer	5.1e-05	0.000229	CcSEcCtD
Galantamine—Insomnia—Docetaxel—prostate cancer	5.1e-05	0.000229	CcSEcCtD
Galantamine—Myalgia—Prednisone—prostate cancer	5.07e-05	0.000228	CcSEcCtD
Galantamine—Arthralgia—Prednisone—prostate cancer	5.07e-05	0.000228	CcSEcCtD
Galantamine—Paraesthesia—Docetaxel—prostate cancer	5.06e-05	0.000227	CcSEcCtD
Galantamine—Anxiety—Prednisone—prostate cancer	5.06e-05	0.000227	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—prostate cancer	5.04e-05	0.000227	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.04e-05	0.000226	CcSEcCtD
Galantamine—Somnolence—Docetaxel—prostate cancer	5.01e-05	0.000225	CcSEcCtD
Galantamine—Discomfort—Prednisone—prostate cancer	5.01e-05	0.000225	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—prostate cancer	5e-05	0.000225	CcSEcCtD
Galantamine—Hypersensitivity—Etoposide—prostate cancer	5e-05	0.000225	CcSEcCtD
Galantamine—Tinnitus—Epirubicin—prostate cancer	4.99e-05	0.000224	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—prostate cancer	4.98e-05	0.000224	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.97e-05	0.000223	CcSEcCtD
Galantamine—Flushing—Epirubicin—prostate cancer	4.97e-05	0.000223	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—prostate cancer	4.97e-05	0.000223	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—prostate cancer	4.97e-05	0.000223	CcSEcCtD
Galantamine—Dyspepsia—Docetaxel—prostate cancer	4.96e-05	0.000223	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—prostate cancer	4.95e-05	0.000222	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—prostate cancer	4.95e-05	0.000222	CcSEcCtD
Galantamine—Insomnia—Capecitabine—prostate cancer	4.94e-05	0.000222	CcSEcCtD
Galantamine—Paraesthesia—Capecitabine—prostate cancer	4.9e-05	0.00022	CcSEcCtD
Galantamine—Decreased appetite—Docetaxel—prostate cancer	4.9e-05	0.00022	CcSEcCtD
Galantamine—Urinary tract disorder—Doxorubicin—prostate cancer	4.89e-05	0.00022	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—prostate cancer	4.88e-05	0.000219	CcSEcCtD
Galantamine—Gastrointestinal disorder—Docetaxel—prostate cancer	4.87e-05	0.000219	CcSEcCtD
Galantamine—Asthenia—Etoposide—prostate cancer	4.87e-05	0.000219	CcSEcCtD
Galantamine—Connective tissue disorder—Doxorubicin—prostate cancer	4.87e-05	0.000219	CcSEcCtD
Galantamine—Fatigue—Docetaxel—prostate cancer	4.86e-05	0.000218	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—prostate cancer	4.86e-05	0.000218	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—prostate cancer	4.86e-05	0.000218	CcSEcCtD
Galantamine—Nausea—Mitoxantrone—prostate cancer	4.85e-05	0.000218	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—prostate cancer	4.84e-05	0.000217	CcSEcCtD
Galantamine—Constipation—Docetaxel—prostate cancer	4.82e-05	0.000217	CcSEcCtD
Galantamine—Dyspepsia—Capecitabine—prostate cancer	4.81e-05	0.000216	CcSEcCtD
Galantamine—Shock—Prednisone—prostate cancer	4.78e-05	0.000215	CcSEcCtD
Galantamine—Arrhythmia—Epirubicin—prostate cancer	4.78e-05	0.000215	CcSEcCtD
Galantamine—Visual impairment—Doxorubicin—prostate cancer	4.77e-05	0.000214	CcSEcCtD
Galantamine—Nervous system disorder—Prednisone—prostate cancer	4.77e-05	0.000214	CcSEcCtD
Galantamine—Tachycardia—Prednisone—prostate cancer	4.75e-05	0.000213	CcSEcCtD
Galantamine—Decreased appetite—Capecitabine—prostate cancer	4.75e-05	0.000213	CcSEcCtD
Galantamine—Skin disorder—Prednisone—prostate cancer	4.72e-05	0.000212	CcSEcCtD
Galantamine—Gastrointestinal disorder—Capecitabine—prostate cancer	4.71e-05	0.000212	CcSEcCtD
Galantamine—Fatigue—Capecitabine—prostate cancer	4.71e-05	0.000211	CcSEcCtD
Galantamine—Hyperhidrosis—Prednisone—prostate cancer	4.7e-05	0.000211	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—prostate cancer	4.69e-05	0.000211	CcSEcCtD
Galantamine—Constipation—Capecitabine—prostate cancer	4.67e-05	0.00021	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—prostate cancer	4.66e-05	0.000209	CcSEcCtD
Galantamine—Feeling abnormal—Docetaxel—prostate cancer	4.65e-05	0.000209	CcSEcCtD
Galantamine—Diarrhoea—Etoposide—prostate cancer	4.64e-05	0.000209	CcSEcCtD
Galantamine—Anorexia—Prednisone—prostate cancer	4.64e-05	0.000208	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—prostate cancer	4.63e-05	0.000208	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—prostate cancer	4.62e-05	0.000207	CcSEcCtD
Galantamine—Gastrointestinal pain—Docetaxel—prostate cancer	4.61e-05	0.000207	CcSEcCtD
Galantamine—Flushing—Doxorubicin—prostate cancer	4.6e-05	0.000206	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—prostate cancer	4.6e-05	0.000206	CcSEcCtD
Galantamine—Flatulence—Epirubicin—prostate cancer	4.59e-05	0.000206	CcSEcCtD
Galantamine—Tension—Epirubicin—prostate cancer	4.57e-05	0.000205	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—prostate cancer	4.56e-05	0.000205	CcSEcCtD
Galantamine—Nervousness—Epirubicin—prostate cancer	4.53e-05	0.000203	CcSEcCtD
Galantamine—Back pain—Epirubicin—prostate cancer	4.51e-05	0.000202	CcSEcCtD
Galantamine—Feeling abnormal—Capecitabine—prostate cancer	4.5e-05	0.000202	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—prostate cancer	4.49e-05	0.000202	CcSEcCtD
Galantamine—Dizziness—Etoposide—prostate cancer	4.49e-05	0.000202	CcSEcCtD
Galantamine—Muscle spasms—Epirubicin—prostate cancer	4.48e-05	0.000201	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—prostate cancer	4.47e-05	0.000201	CcSEcCtD
Galantamine—Gastrointestinal pain—Capecitabine—prostate cancer	4.46e-05	0.000201	CcSEcCtD
Galantamine—Abdominal pain—Docetaxel—prostate cancer	4.46e-05	0.0002	CcSEcCtD
Galantamine—Body temperature increased—Docetaxel—prostate cancer	4.46e-05	0.0002	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Prednisone—prostate cancer	4.43e-05	0.000199	CcSEcCtD
Galantamine—Arrhythmia—Doxorubicin—prostate cancer	4.43e-05	0.000199	CcSEcCtD
Galantamine—Insomnia—Prednisone—prostate cancer	4.4e-05	0.000198	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—prostate cancer	4.39e-05	0.000197	CcSEcCtD
Galantamine—Paraesthesia—Prednisone—prostate cancer	4.37e-05	0.000196	CcSEcCtD
Galantamine—Mental disorder—Doxorubicin—prostate cancer	4.34e-05	0.000195	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—prostate cancer	4.32e-05	0.000194	CcSEcCtD
Galantamine—Body temperature increased—Capecitabine—prostate cancer	4.32e-05	0.000194	CcSEcCtD
Galantamine—Abdominal pain—Capecitabine—prostate cancer	4.32e-05	0.000194	CcSEcCtD
Galantamine—Vomiting—Etoposide—prostate cancer	4.31e-05	0.000194	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—prostate cancer	4.31e-05	0.000194	CcSEcCtD
Galantamine—Anaemia—Epirubicin—prostate cancer	4.31e-05	0.000193	CcSEcCtD
Galantamine—Agitation—Epirubicin—prostate cancer	4.28e-05	0.000192	CcSEcCtD
Galantamine—Dyspepsia—Prednisone—prostate cancer	4.28e-05	0.000192	CcSEcCtD
Galantamine—Rash—Etoposide—prostate cancer	4.28e-05	0.000192	CcSEcCtD
Galantamine—Dermatitis—Etoposide—prostate cancer	4.27e-05	0.000192	CcSEcCtD
Galantamine—Headache—Etoposide—prostate cancer	4.25e-05	0.000191	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—prostate cancer	4.25e-05	0.000191	CcSEcCtD
Galantamine—Tension—Doxorubicin—prostate cancer	4.23e-05	0.00019	CcSEcCtD
Galantamine—Decreased appetite—Prednisone—prostate cancer	4.23e-05	0.00019	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—prostate cancer	4.22e-05	0.00019	CcSEcCtD
Galantamine—Malaise—Epirubicin—prostate cancer	4.2e-05	0.000189	CcSEcCtD
Galantamine—Fatigue—Prednisone—prostate cancer	4.19e-05	0.000188	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—prostate cancer	4.19e-05	0.000188	CcSEcCtD
Galantamine—Vertigo—Epirubicin—prostate cancer	4.19e-05	0.000188	CcSEcCtD
Galantamine—Syncope—Epirubicin—prostate cancer	4.18e-05	0.000188	CcSEcCtD
Galantamine—Back pain—Doxorubicin—prostate cancer	4.17e-05	0.000187	CcSEcCtD
Galantamine—Constipation—Prednisone—prostate cancer	4.16e-05	0.000187	CcSEcCtD
Galantamine—Hypersensitivity—Docetaxel—prostate cancer	4.15e-05	0.000187	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—prostate cancer	4.15e-05	0.000186	CcSEcCtD
Galantamine—Palpitations—Epirubicin—prostate cancer	4.12e-05	0.000185	CcSEcCtD
Galantamine—Loss of consciousness—Epirubicin—prostate cancer	4.1e-05	0.000184	CcSEcCtD
Galantamine—Cough—Epirubicin—prostate cancer	4.07e-05	0.000183	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—prostate cancer	4.06e-05	0.000183	CcSEcCtD
Galantamine—Asthenia—Docetaxel—prostate cancer	4.05e-05	0.000182	CcSEcCtD
Galantamine—Convulsion—Epirubicin—prostate cancer	4.04e-05	0.000181	CcSEcCtD
Galantamine—Nausea—Etoposide—prostate cancer	4.03e-05	0.000181	CcSEcCtD
Galantamine—Hypertension—Epirubicin—prostate cancer	4.02e-05	0.000181	CcSEcCtD
Galantamine—Hypersensitivity—Capecitabine—prostate cancer	4.02e-05	0.000181	CcSEcCtD
Galantamine—Feeling abnormal—Prednisone—prostate cancer	4.01e-05	0.00018	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—prostate cancer	4e-05	0.00018	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—prostate cancer	3.99e-05	0.000179	CcSEcCtD
Galantamine—Gastrointestinal pain—Prednisone—prostate cancer	3.98e-05	0.000179	CcSEcCtD
Galantamine—Chest pain—Epirubicin—prostate cancer	3.97e-05	0.000178	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—prostate cancer	3.97e-05	0.000178	CcSEcCtD
Galantamine—Myalgia—Epirubicin—prostate cancer	3.97e-05	0.000178	CcSEcCtD
Galantamine—Agitation—Doxorubicin—prostate cancer	3.96e-05	0.000178	CcSEcCtD
Galantamine—Anxiety—Epirubicin—prostate cancer	3.95e-05	0.000178	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.94e-05	0.000177	CcSEcCtD
Galantamine—Discomfort—Epirubicin—prostate cancer	3.92e-05	0.000176	CcSEcCtD
Galantamine—Asthenia—Capecitabine—prostate cancer	3.92e-05	0.000176	CcSEcCtD
Galantamine—Malaise—Doxorubicin—prostate cancer	3.89e-05	0.000175	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—prostate cancer	3.88e-05	0.000174	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—prostate cancer	3.87e-05	0.000174	CcSEcCtD
Galantamine—Syncope—Doxorubicin—prostate cancer	3.87e-05	0.000174	CcSEcCtD
Galantamine—Diarrhoea—Docetaxel—prostate cancer	3.86e-05	0.000173	CcSEcCtD
Galantamine—Body temperature increased—Prednisone—prostate cancer	3.84e-05	0.000173	CcSEcCtD
Galantamine—Abdominal pain—Prednisone—prostate cancer	3.84e-05	0.000173	CcSEcCtD
Galantamine—Confusional state—Epirubicin—prostate cancer	3.84e-05	0.000172	CcSEcCtD
Galantamine—Palpitations—Doxorubicin—prostate cancer	3.81e-05	0.000171	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—prostate cancer	3.79e-05	0.00017	CcSEcCtD
Galantamine—Cough—Doxorubicin—prostate cancer	3.76e-05	0.000169	CcSEcCtD
Galantamine—Shock—Epirubicin—prostate cancer	3.74e-05	0.000168	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—prostate cancer	3.74e-05	0.000168	CcSEcCtD
Galantamine—Diarrhoea—Capecitabine—prostate cancer	3.74e-05	0.000168	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—prostate cancer	3.73e-05	0.000168	CcSEcCtD
Galantamine—Dizziness—Docetaxel—prostate cancer	3.73e-05	0.000167	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—prostate cancer	3.72e-05	0.000167	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—prostate cancer	3.72e-05	0.000167	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—prostate cancer	3.71e-05	0.000167	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—prostate cancer	3.69e-05	0.000166	CcSEcCtD
Galantamine—Hyperhidrosis—Epirubicin—prostate cancer	3.68e-05	0.000165	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—prostate cancer	3.67e-05	0.000165	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—prostate cancer	3.67e-05	0.000165	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—prostate cancer	3.67e-05	0.000165	CcSEcCtD
Galantamine—Anxiety—Doxorubicin—prostate cancer	3.66e-05	0.000164	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.65e-05	0.000164	CcSEcCtD
Galantamine—Discomfort—Doxorubicin—prostate cancer	3.63e-05	0.000163	CcSEcCtD
Galantamine—Anorexia—Epirubicin—prostate cancer	3.63e-05	0.000163	CcSEcCtD
Galantamine—Dizziness—Capecitabine—prostate cancer	3.61e-05	0.000162	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—prostate cancer	3.59e-05	0.000161	CcSEcCtD
Galantamine—Vomiting—Docetaxel—prostate cancer	3.59e-05	0.000161	CcSEcCtD
Galantamine—Hypersensitivity—Prednisone—prostate cancer	3.58e-05	0.000161	CcSEcCtD
Galantamine—Rash—Docetaxel—prostate cancer	3.56e-05	0.00016	CcSEcCtD
Galantamine—Hypotension—Epirubicin—prostate cancer	3.55e-05	0.00016	CcSEcCtD
Galantamine—Dermatitis—Docetaxel—prostate cancer	3.55e-05	0.00016	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—prostate cancer	3.55e-05	0.000159	CcSEcCtD
Galantamine—Headache—Docetaxel—prostate cancer	3.53e-05	0.000159	CcSEcCtD
Galantamine—Asthenia—Prednisone—prostate cancer	3.49e-05	0.000157	CcSEcCtD
Galantamine—Vomiting—Capecitabine—prostate cancer	3.47e-05	0.000156	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.47e-05	0.000156	CcSEcCtD
Galantamine—Shock—Doxorubicin—prostate cancer	3.46e-05	0.000156	CcSEcCtD
Galantamine—Nervous system disorder—Doxorubicin—prostate cancer	3.45e-05	0.000155	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—prostate cancer	3.45e-05	0.000155	CcSEcCtD
Galantamine—Rash—Capecitabine—prostate cancer	3.44e-05	0.000155	CcSEcCtD
Galantamine—Insomnia—Epirubicin—prostate cancer	3.44e-05	0.000155	CcSEcCtD
Galantamine—Dermatitis—Capecitabine—prostate cancer	3.44e-05	0.000154	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—prostate cancer	3.44e-05	0.000154	CcSEcCtD
Galantamine—Headache—Capecitabine—prostate cancer	3.42e-05	0.000154	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—prostate cancer	3.42e-05	0.000154	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—prostate cancer	3.42e-05	0.000153	CcSEcCtD
Galantamine—Hyperhidrosis—Doxorubicin—prostate cancer	3.4e-05	0.000153	CcSEcCtD
Galantamine—Somnolence—Epirubicin—prostate cancer	3.38e-05	0.000152	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—prostate cancer	3.35e-05	0.000151	CcSEcCtD
Galantamine—Nausea—Docetaxel—prostate cancer	3.35e-05	0.00015	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—prostate cancer	3.35e-05	0.00015	CcSEcCtD
Galantamine—Diarrhoea—Prednisone—prostate cancer	3.33e-05	0.000149	CcSEcCtD
Galantamine—Decreased appetite—Epirubicin—prostate cancer	3.31e-05	0.000149	CcSEcCtD
Galantamine—Hypotension—Doxorubicin—prostate cancer	3.29e-05	0.000148	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—prostate cancer	3.28e-05	0.000147	CcSEcCtD
Galantamine—Fatigue—Epirubicin—prostate cancer	3.28e-05	0.000147	CcSEcCtD
Galantamine—Constipation—Epirubicin—prostate cancer	3.25e-05	0.000146	CcSEcCtD
Galantamine—Nausea—Capecitabine—prostate cancer	3.24e-05	0.000146	CcSEcCtD
Galantamine—Dizziness—Prednisone—prostate cancer	3.22e-05	0.000144	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.21e-05	0.000144	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—prostate cancer	3.18e-05	0.000143	CcSEcCtD
Galantamine—Paraesthesia—Doxorubicin—prostate cancer	3.16e-05	0.000142	CcSEcCtD
Galantamine—Feeling abnormal—Epirubicin—prostate cancer	3.13e-05	0.000141	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—prostate cancer	3.13e-05	0.000141	CcSEcCtD
Galantamine—Gastrointestinal pain—Epirubicin—prostate cancer	3.11e-05	0.00014	CcSEcCtD
Galantamine—Dyspepsia—Doxorubicin—prostate cancer	3.1e-05	0.000139	CcSEcCtD
Galantamine—Vomiting—Prednisone—prostate cancer	3.09e-05	0.000139	CcSEcCtD
Galantamine—Rash—Prednisone—prostate cancer	3.07e-05	0.000138	CcSEcCtD
Galantamine—Dermatitis—Prednisone—prostate cancer	3.06e-05	0.000138	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—prostate cancer	3.06e-05	0.000137	CcSEcCtD
Galantamine—Headache—Prednisone—prostate cancer	3.05e-05	0.000137	CcSEcCtD
Galantamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.04e-05	0.000136	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—prostate cancer	3.03e-05	0.000136	CcSEcCtD
Galantamine—Constipation—Doxorubicin—prostate cancer	3.01e-05	0.000135	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—prostate cancer	3.01e-05	0.000135	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—prostate cancer	3.01e-05	0.000135	CcSEcCtD
Galantamine—Feeling abnormal—Doxorubicin—prostate cancer	2.9e-05	0.00013	CcSEcCtD
Galantamine—Nausea—Prednisone—prostate cancer	2.89e-05	0.00013	CcSEcCtD
Galantamine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.88e-05	0.000129	CcSEcCtD
Galantamine—Hypersensitivity—Epirubicin—prostate cancer	2.8e-05	0.000126	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—prostate cancer	2.78e-05	0.000125	CcSEcCtD
Galantamine—Body temperature increased—Doxorubicin—prostate cancer	2.78e-05	0.000125	CcSEcCtD
Galantamine—Asthenia—Epirubicin—prostate cancer	2.73e-05	0.000123	CcSEcCtD
Galantamine—Diarrhoea—Epirubicin—prostate cancer	2.6e-05	0.000117	CcSEcCtD
Galantamine—Hypersensitivity—Doxorubicin—prostate cancer	2.59e-05	0.000116	CcSEcCtD
Galantamine—Asthenia—Doxorubicin—prostate cancer	2.53e-05	0.000113	CcSEcCtD
Galantamine—Dizziness—Epirubicin—prostate cancer	2.52e-05	0.000113	CcSEcCtD
Galantamine—Vomiting—Epirubicin—prostate cancer	2.42e-05	0.000109	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—prostate cancer	2.41e-05	0.000108	CcSEcCtD
Galantamine—Rash—Epirubicin—prostate cancer	2.4e-05	0.000108	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—prostate cancer	2.4e-05	0.000108	CcSEcCtD
Galantamine—Headache—Epirubicin—prostate cancer	2.38e-05	0.000107	CcSEcCtD
Galantamine—Dizziness—Doxorubicin—prostate cancer	2.33e-05	0.000105	CcSEcCtD
Galantamine—Nausea—Epirubicin—prostate cancer	2.26e-05	0.000101	CcSEcCtD
Galantamine—Vomiting—Doxorubicin—prostate cancer	2.24e-05	0.000101	CcSEcCtD
Galantamine—Rash—Doxorubicin—prostate cancer	2.22e-05	9.97e-05	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—prostate cancer	2.22e-05	9.96e-05	CcSEcCtD
Galantamine—Headache—Doxorubicin—prostate cancer	2.2e-05	9.9e-05	CcSEcCtD
Galantamine—Nausea—Doxorubicin—prostate cancer	2.09e-05	9.39e-05	CcSEcCtD
Galantamine—CYP2D6—Metabolism—TNFRSF21—prostate cancer	7.53e-06	7.21e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GGT1—prostate cancer	7.53e-06	7.21e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC5A5—prostate cancer	7.49e-06	7.17e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GRHL1—prostate cancer	7.43e-06	7.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PSAT1—prostate cancer	7.43e-06	7.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ADI1—prostate cancer	7.43e-06	7.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TST—prostate cancer	7.43e-06	7.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CSAD—prostate cancer	7.43e-06	7.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CBR1—prostate cancer	7.43e-06	7.12e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NCOA1—prostate cancer	7.41e-06	7.1e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MTAP—prostate cancer	7.32e-06	7.02e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP7B1—prostate cancer	7.32e-06	7.02e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP2E1—prostate cancer	7.31e-06	7.01e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGF1—prostate cancer	7.31e-06	7.01e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP19A1—prostate cancer	7.31e-06	7e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NQO1—prostate cancer	7.23e-06	6.93e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SRD5A1—prostate cancer	7.14e-06	6.84e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SULT1E1—prostate cancer	7.14e-06	6.84e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TH—prostate cancer	7.13e-06	6.83e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.08e-06	6.78e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—MMP2—prostate cancer	7.08e-06	6.78e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP3A4—prostate cancer	7.05e-06	6.76e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—RXRA—prostate cancer	7.05e-06	6.76e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.02e-06	6.72e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP1B1—prostate cancer	6.93e-06	6.64e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—UGT2B17—prostate cancer	6.91e-06	6.62e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—UGT2B15—prostate cancer	6.91e-06	6.62e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GRHPR—prostate cancer	6.91e-06	6.62e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CKMT2—prostate cancer	6.91e-06	6.62e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.86e-06	6.57e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ACSL4—prostate cancer	6.81e-06	6.52e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HSD17B3—prostate cancer	6.81e-06	6.52e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—COMT—prostate cancer	6.79e-06	6.51e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTP1—prostate cancer	6.76e-06	6.48e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GGT1—prostate cancer	6.71e-06	6.43e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ITPR1—prostate cancer	6.65e-06	6.37e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NCOA1—prostate cancer	6.61e-06	6.34e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CXCL8—prostate cancer	6.59e-06	6.32e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.54e-06	6.27e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PHGDH—prostate cancer	6.53e-06	6.25e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—UMPS—prostate cancer	6.53e-06	6.25e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ARG2—prostate cancer	6.53e-06	6.25e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP19A1—prostate cancer	6.52e-06	6.25e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SULT2B1—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PGAM2—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AOX1—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RFK—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MBTPS1—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTM3—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NAGLU—prostate cancer	6.49e-06	6.22e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—LDHB—prostate cancer	6.4e-06	6.13e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—RXRA—prostate cancer	6.29e-06	6.03e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TYMS—prostate cancer	6.28e-06	6.02e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP3A5—prostate cancer	6.28e-06	6.02e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTM1—prostate cancer	6.21e-06	5.95e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP3A43—prostate cancer	6.16e-06	5.9e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AMACR—prostate cancer	6.16e-06	5.9e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NAT1—prostate cancer	6.16e-06	5.9e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SRD5A2—prostate cancer	6.16e-06	5.9e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—DEGS1—prostate cancer	6.16e-06	5.9e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.12e-06	5.86e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—LPL—prostate cancer	6.1e-06	5.84e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CTNNB1—prostate cancer	6.08e-06	5.83e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PDHA1—prostate cancer	6.07e-06	5.81e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTA3—prostate cancer	6.07e-06	5.81e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—UCP3—prostate cancer	6.07e-06	5.81e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TCN2—prostate cancer	6.07e-06	5.81e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—COMT—prostate cancer	6.06e-06	5.81e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTP1—prostate cancer	6.03e-06	5.78e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ITPR1—prostate cancer	5.93e-06	5.69e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP1A1—prostate cancer	5.89e-06	5.64e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CXCL8—prostate cancer	5.88e-06	5.63e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HSD17B1—prostate cancer	5.87e-06	5.63e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ERCC2—prostate cancer	5.84e-06	5.6e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.84e-06	5.59e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HSD3B1—prostate cancer	5.79e-06	5.55e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC22A3—prostate cancer	5.79e-06	5.55e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TYMS—prostate cancer	5.61e-06	5.37e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTA4—prostate cancer	5.55e-06	5.32e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TBXAS1—prostate cancer	5.55e-06	5.32e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTM1—prostate cancer	5.54e-06	5.31e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MTHFR—prostate cancer	5.49e-06	5.26e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—LPL—prostate cancer	5.44e-06	5.21e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CTNNB1—prostate cancer	5.42e-06	5.2e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTA2—prostate cancer	5.41e-06	5.18e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PPARA—prostate cancer	5.39e-06	5.16e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SULT1A1—prostate cancer	5.34e-06	5.12e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ABCG5—prostate cancer	5.34e-06	5.12e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP1A1—prostate cancer	5.25e-06	5.03e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HPGD—prostate cancer	5.23e-06	5.02e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—B4GALT4—prostate cancer	5.23e-06	5.02e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTA1—prostate cancer	5.22e-06	5e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ERCC2—prostate cancer	5.21e-06	4.99e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HSD3B2—prostate cancer	5.16e-06	4.94e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTO1—prostate cancer	5.16e-06	4.94e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NAT2—prostate cancer	5.16e-06	4.94e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CAV1—prostate cancer	5.06e-06	4.85e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PLCB2—prostate cancer	4.95e-06	4.74e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—LRP2—prostate cancer	4.95e-06	4.74e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP2C18—prostate cancer	4.95e-06	4.74e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TNFRSF21—prostate cancer	4.92e-06	4.72e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MTHFR—prostate cancer	4.9e-06	4.69e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—P4HB—prostate cancer	4.85e-06	4.65e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.84e-06	4.64e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PPARA—prostate cancer	4.81e-06	4.6e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP7B1—prostate cancer	4.79e-06	4.59e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MTAP—prostate cancer	4.79e-06	4.59e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC22A1—prostate cancer	4.72e-06	4.52e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SULT1E1—prostate cancer	4.67e-06	4.47e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SRD5A1—prostate cancer	4.67e-06	4.47e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CG—prostate cancer	4.61e-06	4.42e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SULT2A1—prostate cancer	4.6e-06	4.41e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MED12—prostate cancer	4.52e-06	4.34e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CAV1—prostate cancer	4.52e-06	4.33e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GNG5—prostate cancer	4.49e-06	4.3e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HSD17B3—prostate cancer	4.45e-06	4.27e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ACSL4—prostate cancer	4.45e-06	4.27e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—INS—prostate cancer	4.37e-06	4.18e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NCOA3—prostate cancer	4.32e-06	4.14e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.32e-06	4.14e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CREBBP—prostate cancer	4.28e-06	4.1e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—UMPS—prostate cancer	4.27e-06	4.09e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PHGDH—prostate cancer	4.27e-06	4.09e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ARG2—prostate cancer	4.27e-06	4.09e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—LDHB—prostate cancer	4.18e-06	4.01e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HPGDS—prostate cancer	4.12e-06	3.95e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CG—prostate cancer	4.12e-06	3.94e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.11e-06	3.94e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP2C19—prostate cancer	4.1e-06	3.93e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CD—prostate cancer	4.06e-06	3.89e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ACHE—prostate cancer	4e-06	3.83e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTT1—prostate cancer	4e-06	3.83e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TCN2—prostate cancer	3.97e-06	3.8e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTA3—prostate cancer	3.97e-06	3.8e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PDHA1—prostate cancer	3.97e-06	3.8e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—UCP3—prostate cancer	3.97e-06	3.8e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP2A6—prostate cancer	3.95e-06	3.79e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—INS—prostate cancer	3.9e-06	3.73e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKR1C3—prostate cancer	3.85e-06	3.69e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NOS3—prostate cancer	3.83e-06	3.67e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PRKACB—prostate cancer	3.83e-06	3.67e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CREBBP—prostate cancer	3.82e-06	3.66e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP17A1—prostate cancer	3.79e-06	3.63e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HSD3B1—prostate cancer	3.78e-06	3.63e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC22A3—prostate cancer	3.78e-06	3.63e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTA4—prostate cancer	3.63e-06	3.48e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.63e-06	3.48e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CD—prostate cancer	3.62e-06	3.47e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NCOA2—prostate cancer	3.61e-06	3.46e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTA2—prostate cancer	3.54e-06	3.39e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CB—prostate cancer	3.53e-06	3.39e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS2—prostate cancer	3.5e-06	3.36e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.49e-06	3.35e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ABCG5—prostate cancer	3.49e-06	3.35e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC5A5—prostate cancer	3.44e-06	3.3e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NOS3—prostate cancer	3.42e-06	3.27e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTA1—prostate cancer	3.41e-06	3.27e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NAT2—prostate cancer	3.37e-06	3.23e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.37e-06	3.23e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTO1—prostate cancer	3.37e-06	3.23e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP2E1—prostate cancer	3.36e-06	3.22e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NQO1—prostate cancer	3.32e-06	3.19e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TH—prostate cancer	3.28e-06	3.14e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP3A4—prostate cancer	3.24e-06	3.11e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PLCB2—prostate cancer	3.23e-06	3.1e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.23e-06	3.1e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—LRP2—prostate cancer	3.23e-06	3.1e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP1B1—prostate cancer	3.19e-06	3.05e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—P4HB—prostate cancer	3.17e-06	3.04e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CB—prostate cancer	3.15e-06	3.02e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS2—prostate cancer	3.12e-06	2.99e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GGT1—prostate cancer	3.09e-06	2.96e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.09e-06	2.96e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTEN—prostate cancer	3.05e-06	2.93e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NCOA1—prostate cancer	3.04e-06	2.91e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.01e-06	2.88e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP19A1—prostate cancer	3e-06	2.87e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MED12—prostate cancer	2.96e-06	2.83e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GNG5—prostate cancer	2.93e-06	2.81e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—EP300—prostate cancer	2.91e-06	2.79e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—RXRA—prostate cancer	2.89e-06	2.77e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NCOA3—prostate cancer	2.83e-06	2.71e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—COMT—prostate cancer	2.79e-06	2.67e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTP1—prostate cancer	2.77e-06	2.66e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ITPR1—prostate cancer	2.73e-06	2.61e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTEN—prostate cancer	2.72e-06	2.61e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HPGDS—prostate cancer	2.7e-06	2.58e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.68e-06	2.57e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ACHE—prostate cancer	2.62e-06	2.51e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTT1—prostate cancer	2.62e-06	2.51e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—EP300—prostate cancer	2.6e-06	2.49e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.59e-06	2.48e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TYMS—prostate cancer	2.58e-06	2.47e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTM1—prostate cancer	2.55e-06	2.44e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.52e-06	2.41e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PRKACB—prostate cancer	2.5e-06	2.4e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—LPL—prostate cancer	2.5e-06	2.4e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.48e-06	2.37e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.42e-06	2.31e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ERCC2—prostate cancer	2.4e-06	2.3e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NCOA2—prostate cancer	2.36e-06	2.26e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.25e-06	2.16e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.25e-06	2.16e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PPARA—prostate cancer	2.21e-06	2.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.2e-06	2.11e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NQO1—prostate cancer	2.17e-06	2.08e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CA—prostate cancer	2.15e-06	2.06e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TH—prostate cancer	2.14e-06	2.05e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.08e-06	2e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CAV1—prostate cancer	2.08e-06	1.99e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GGT1—prostate cancer	2.02e-06	1.93e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.99e-06	1.91e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.96e-06	1.88e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CA—prostate cancer	1.92e-06	1.84e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.89e-06	1.81e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RXRA—prostate cancer	1.89e-06	1.81e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—COMT—prostate cancer	1.82e-06	1.75e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.81e-06	1.74e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—INS—prostate cancer	1.79e-06	1.72e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.78e-06	1.71e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKT1—prostate cancer	1.76e-06	1.69e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CREBBP—prostate cancer	1.75e-06	1.68e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TYMS—prostate cancer	1.69e-06	1.62e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.67e-06	1.6e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.66e-06	1.59e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—LPL—prostate cancer	1.64e-06	1.57e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.58e-06	1.51e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NOS3—prostate cancer	1.57e-06	1.51e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKT1—prostate cancer	1.57e-06	1.5e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.57e-06	1.5e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.47e-06	1.41e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.45e-06	1.39e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PPARA—prostate cancer	1.44e-06	1.38e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.44e-06	1.38e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CAV1—prostate cancer	1.36e-06	1.3e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTEN—prostate cancer	1.25e-06	1.2e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.24e-06	1.19e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—EP300—prostate cancer	1.19e-06	1.14e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—INS—prostate cancer	1.17e-06	1.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.15e-06	1.1e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.09e-06	1.04e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NOS3—prostate cancer	1.03e-06	9.84e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CB—prostate cancer	9.48e-07	9.08e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS2—prostate cancer	9.39e-07	9e-06	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CA—prostate cancer	8.84e-07	8.47e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTEN—prostate cancer	8.19e-07	7.85e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—EP300—prostate cancer	7.81e-07	7.49e-06	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKT1—prostate cancer	7.22e-07	6.92e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.78e-07	5.54e-06	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKT1—prostate cancer	4.72e-07	4.52e-06	CbGpPWpGaD
